Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib in SLE
NCT05688696Phase 2Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Apr 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of orelabrutinib in systemic lupus erythematosus (SLE) (3 arms), sponsored by InnoCare Pharma. Primary endpoint: SLE Responder Index - 4 Response Rate at Week 48. Started Apr 2023; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05688696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05688696.